Guggenheim analyst Brad Canino lowered the firm's price target on Syndax (SNDX) to $31 from $34 and keeps a Buy rating on the shares. The firm updated its acute myeloid leukemia market model based on new learnings about the duration of revumenib post-transplant maintenance from recent medical meeting presentations and also incorporated recent commercial commentary from Syndax and Kura Oncology (KURA), the analyst tells investors.
